Table 4.
Vaccine | PRNT50 value (mIU/mL) on study day | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Day 0 | Day 30 | Day 60 | Day 90 | Day 104 | ||||||
Mean | SEM | Mean | SEM | Mean | SEM | Mean | SEM | Mean | SEM | |
YFE-1 | 108 | 0 | 267* | 72.6 | 1,427** | 729 | 3,316 | 1,469 | 9,172* | 2,770 |
YFE-2E | 108 | 0 | 192** | 8.4 | 1,534** | 266 | 1,360* | 286.6 | 14,114* | 8,054 |
Mock | 108 | 0 | 199 | 20 | 170.6 | 11.9 | 162 | 0 | 6,995 | 3,995 |
Clean | 108 | 0 | 199 | 20 | 170.6 | 11.9 | 161 | 0.8 | 16,366 | 9,100 |
17DD | 108 | 0 | 13,028 | 1,983 | 28,187 | 6,421 | 13,710 | 1,911 | 102,180 | 10,136 |
PRNT50 = plaque-reduction neutralization test; SEM = standard error of the mean; YFE = yellow fever virus envelope protein.
P < 0.05 and **P < 0.01 when YFE-1, YFE-2E, and 17DD groups were compared (Kruskal–Wallis test).